Literature DB >> 30746598

Correlation Between Intraoperative and Pathological Findings for Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.

Y Berger1, H Jacoby2, M I Kaufmann3, A Ben-Yaacov4, G Westreich4, I Sharon4, L Barda2, N Sharif2, R Nadler2, N Horesh2, A Nissan4, M Gutman2, A Hoffman2.   

Abstract

BACKGROUND: This study aimed to examine the correlation between intraoperative and pathological findings for patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) and to determine their prognostic significance.
METHODS: Pathological reports of all colorectal cancer (CRC) patients undergoing CRS/HIPEC between 2009 and 2016 were retrospectively reviewed. Pathological specimens lacking tumor cells were defined as negative pathological specimens (NPS). The intraoperative peritoneal cancer index (PCI) and pathological PCI (excluding NPS) were calculated separately. Receiver operating characteristic (ROC) curves were applied to compare the prognostic value of intraoperative and pathological scoring systems.
RESULTS: For 108 CRC patients, 113 CRS/HIPEC procedures were performed. Of 959 pathological specimens examined, 178 (18.6%) were NPS. Overall, 78 procedures (69%) showed NPS. In 52 procedures (46%), the pathological PCI differed from the intraoperative PCI (∆PCI > 0). The ROC areas for intraoperative PCI and pathological PCI were similar in predicting 1-year overall survival (OS), 2-year OS, and 1-year disease-free survival (all p values not significant). However, for the patients with NPS, the number of positive specimens (containing tumor tissue) was superior to intraoperative PCI in predicting 2-year OS (ROC under the curve areas, 0.69 vs. 0.58, respectively; p = 0.012). In addition, a subgroup of 15 patients with a high ∆PCI (≥ 3) had a more favorable median OS than a matched group of 30 patients with similar intraoperative PCI and a ∆PCI of 0 (median survival not reached vs. 21.6 months, respectively; p = 0.05).
CONCLUSIONS: In the majority of CRC CRS/HIPEC procedures, NPS may be found. Among patients with NPS, pathological correlation may have a prognostic significance.

Entities:  

Mesh:

Year:  2019        PMID: 30746598     DOI: 10.1245/s10434-019-07219-9

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  7 in total

Review 1.  Advances in the management of peritoneal malignancies.

Authors:  Vahan Kepenekian; Aditi Bhatt; Julien Péron; Mohammad Alyami; Nazim Benzerdjeb; Naoual Bakrin; Claire Falandry; Guillaume Passot; Pascal Rousset; Olivier Glehen
Journal:  Nat Rev Clin Oncol       Date:  2022-09-07       Impact factor: 65.011

2.  Clinical and Radiologic Predictors of a Pathologic Complete Response to Neoadjuvant Chemotherapy (NACT) in Patients Undergoing Cytoreductive Surgery for Colorectal Peritoneal Metastases: Results of a Prospective Multi-center Study.

Authors:  Aditi Bhatt; Pascal Rousset; Nazim Benzerdjeb; Praveen Kammar; Sanket Mehta; Loma Parikh; Gaurav Goswami; Sakina Shaikh; Vahan Kepenekian; Guillaume Passot; Olivier Glehen
Journal:  Ann Surg Oncol       Date:  2020-11-18       Impact factor: 5.344

3.  Ratio of Pathological Response to Preoperative Chemotherapy in Patients Undergoing Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Metastatic Colorectal Cancer Correlates with Survival.

Authors:  Eyal Mor; Dan Assaf; Shachar Laks; Haggai Benvenisti; Gal Schtrechman; David Hazzan; Lior Segev; Ronel Yaka; Einat Shacham-Shmueli; Ofer Margalit; Naama Halpern; Daria Perelson; Monica-Inda Kaufmann; Almog Ben-Yaacov; Aviram Nissan; Mohammad Adileh
Journal:  Ann Surg Oncol       Date:  2021-07-07       Impact factor: 5.344

4.  ASO Author Reflections: Pathologic Response Ratio (PRR) in CRS and HIPEC for Peritoneal Metastasis from Colorectal Cancer.

Authors:  Eyal Mor; Shachar Laks; Aviram Nissan; Mohammad Adileh
Journal:  Ann Surg Oncol       Date:  2021-06-27       Impact factor: 5.344

5.  CT Enterography for Preoperative Evaluation of Peritoneal Carcinomatosis Index in Advanced Ovarian Cancer.

Authors:  Katty Delgado-Barriga; Carmen Medina; Luis Gomez-Quiles; Santiago F Marco-Domenech; Javier Escrig; Antoni Llueca
Journal:  J Clin Med       Date:  2022-01-18       Impact factor: 4.241

6.  Heterogeneity of Mismatch Repair Status and Microsatellite Instability between Primary Tumour and Metastasis and Its Implications for Immunotherapy in Colorectal Cancers.

Authors:  Camille Evrard; Stéphane Messina; David Sefrioui; Éric Frouin; Marie-Luce Auriault; Romain Chautard; Aziz Zaanan; Marion Jaffrelot; Christelle De La Fouchardière; Thomas Aparicio; Romain Coriat; Julie Godet; Christine Silvain; Violaine Randrian; Jean-Christophe Sabourin; Rosine Guimbaud; Elodie Miquelestorena-Standley; Thierry Lecomte; Valérie Moulin; Lucie Karayan-Tapon; Gaëlle Tachon; David Tougeron
Journal:  Int J Mol Sci       Date:  2022-04-17       Impact factor: 6.208

7.  Patterns of peritoneal dissemination and response to systemic chemotherapy in common and rare peritoneal tumours treated by cytoreductive surgery: study protocol of a prospective, multicentre, observational study.

Authors:  Aditi Bhatt; Pascal Rousset; Dario Baratti; Daniele Biacchi; Nazim Benzerdjeb; Ignace H J T de Hingh; Marcello Deraco; Vadim Gushchin; Praveen Kammar; Daniel Labow; Edward Levine; Brendan Moran; Faheez Mohamed; David Morris; Sanket Mehta; Aviram Nissan; Mohammad Alyami; Mohammad Adileh; Shoma Barat; Almog Ben Yacov; Kurtis Campbell; Kathleen Cummins-Perry; Delia Cortes-Guiral; Noah Cohen; Loma Parikh; Samer Alammari; Galal Bashanfer; Anwar Alshukami; Kaushal Kundalia; Gaurav Goswami; Vincent van de Vlasakker; Michelle Sittig; Paolo Sammartino; Armando Sardi; Laurent Villeneuve; Kiran Turaga; Yutaka Yonemura; Olivier Glehen
Journal:  BMJ Open       Date:  2021-07-05       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.